Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort.
Elom Kouassivi AglagoSabina RinaldiHeinz FreislingLi JiaoDavid J HughesVeronika FedirkoCasper G SchalkwijkElisabete WeiderpassChristina Catherine DahmKim OvervadAnne Kirstine EriksenCecilie KyroMarie-Christine Boutron-RuaultJoseph A RothwellGianluca SeveriVerena A KatzkeTilman KühnMatthias Bernd SchulzeKrasimira AleksandrovaGiovanna MasalaVittorio KroghSalvatore PanicoRosario TuminoAlessio NaccaratiBas Bueno-de-MesquitaCarla H van GilsTorkjel M SandangerInger Torhild GramGuri SkeieJ Ramón QuirósPaula JakszynMaria-José SánchezPilar AmianoJosé María HouertaEva ArdanazIngegerd JohanssonSophia HarlidAurora Perez-CornagoAna-Lucia MayénReynalda CordovaMarc J GunterPaolo VineisAmanda J CrossElio RiboliMazda JenabPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020)
Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in colorectal cancer development.
Keyphrases